Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, shares the results of the BTM-CTN 1506 (MORPHO; NCT02997202) Phase III study evaluating gilteritinib as a post-transplant maintenance therapy for patients with acute myeloid leukemia (AML) carrying an internal tandem duplication mutation of FLT3 (FLT3-ITD). Whilst the study did not show a benefit for gilteritinib in all patients, its positive effect was more pronounced in patients who were measurable residual disease (MRD)-positive before allogeneic transplantation. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть